NDAORALSOLUTION
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOWTUSS is an oral solution combining guaifenesin (an expectorant) and hydrocodone bitartrate (an opioid cough suppressant) indicated for productive cough management. This combination targets both mucus clearance and cough reflex suppression, providing dual-mechanism relief for respiratory symptoms.
Peak
Product is in peak commercial phase with moderate competitive pressure (30/100), suggesting stable but challenged revenue requiring defensive marketing strategies and team focus on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FLOWTUSS positions you in a mature, stable product requiring defensive commercial execution and regulatory compliance expertise, particularly around opioid prescribing controls. Career growth is likely limited by peak lifecycle stage, but offers deep expertise in cough-suppressant market dynamics and opioid stewardship.
Brand ManagerField Sales Representative
Worked on FLOWTUSS at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.